3.4 Doxorubicin Doxorubicin (DOX) is an anthracycline antitumor drug discovered in 1969
Our analyses demonstrated that PD patients exhibit significant metabolic reprogramming, characterized by a shift in energy metabolism from the tricarboxylic acid cycle toward glycolysis, a dysregulated urea cycle, and lipid remodeling, as well as extensive activation of inflammatory and immune responses involving the PI3K-Akt, IL-17, NF-kappaB, MAPK and TNF signaling pathways
The high GSH/GSSG ratio provides the essential reducing environment inside the cell
Application: Cosmetic formulations
However, those with asthma, certain allergies, or specific chronic illnesses should consult a medical professional before beginning treatment